您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (8): 80-85.doi: 10.6040/j.issn.1671-7554.0.2021.0440

• • 上一篇    下一篇

丙戊酸对134例放疗神经胶质瘤患者预后生存和肿瘤复发的影响

孙庆杰1,张怡莎1,管尚慧2,凤志慧1   

  • 出版日期:2021-08-10 发布日期:2021-09-16
  • 通讯作者: 凤志慧. E-mail:fengzhihui@sdu.edu.cn
  • 基金资助:
    2019年山东省重点研发计划(2019GSF108083);山东省自然科学基金(ZR2020MH330)

Effects of valproic acid on the survival and tumor recurrence of 134 patients with glioma treated with radiotherapy

SUN Qingjie1, ZHANG Yisha1, GUAN Shanghui2, FENG Zhihui1   

  1. 1. Department of Occupational and Environmental Health, School of Public Health, Shandong University, Jinan 250012, Shandong, China;
    2. Department of Oncology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Online:2021-08-10 Published:2021-09-16

摘要: 目的 通过丙戊酸(VPA)对放疗神经胶质瘤患者预后生存与肿瘤复发影响的分析,旨在从临床角度提供VPA增强放射对肿瘤生长的抑制和延长患者生存时间作用的研究依据。 方法 回顾性研究数据来自2012~2016年山东大学齐鲁医院肿瘤科接受手术和放疗的134例胶质瘤患者,收集患者的临床信息及随访记录,采用多因素Cox比例风险模型分析这些神经胶质瘤患者服用VPA对总生存期(OS)和无进展生存期(PFS)的影响。 结果 134例胶质瘤患者OS中位生存期为49个月,PFS中位生存期为52个月。单因素分析结果显示,VPA、病理分级、年龄和化疗与胶质瘤患者预后有关联(P<0.05);多因素分析在调整了年龄、病理分级和化疗的作用后,显示患者术后放疗并服用VPA可以改善胶质瘤患者的OS(HR=0.49,95%CI:0.30~0.80)和PFS(HR=0.56,95%CI:0.33~0.93)。 结论 VPA可以显著提高放疗神经胶质瘤患者生存时间,并且降低肿瘤的复发。

关键词: 神经胶质瘤, 丙戊酸, 总生存期, 无进展生存期

Abstract: Objective To analyze the effects of valproic acid(VPA)on the prognostic survival and tumor recurrence of patients with glioma treated with radiotherapy, so as to provide a clinical basis for the study of the effect of VPA on enhancing the inhibition of tumor growth by radiation and prolonging the survival time of patients. Methods The clinical and follow-up data of 134 glioma patients who underwent surgery and radiotherapy in the Oncology Department of Qilu Hospital, Shandong University during 2012 and 2016 were retrospectively analyzed. The effects of VPA on overall survival(OS)and progression-free survival(PFS)were analyzed with multivariate Cox proportional hazard model. Results The median OS and PFS were 49 and 52 months, respectively. Univariate analysis showed VPA, pathological grade, age and chemotherapy were associated with the prognosis(P<0.05). Multivariate analysis showed, after adjustment of age, pathological grade and the effects of chemotherapy, VPA improved the OS(HR=0.49, 95%CI: 0.30-0.80)and PFS(HR=0.56, 95%CI: 0.33-0.93). Conclusion VPA can significantly prolong the survival time of patients with glioma and reduce tumor recurrence.

Key words: Glioma, Valproic acid, Overall survival, Progression-free survival

中图分类号: 

  • R730.7
[1] Zhang X, Yang H, Gong B, et al. Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis [J]. J Neurooncol, 2012, 107(2): 281-288.
[2] Watanabe S, Kuwabara Y, Suehiro S, et al. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma [J]. Eur J Clin Pharmacol, 2017, 73(3): 357-363.
[3] Saeed H, Tseng YD, Lo SS. Narrative review of palliative hypofractionated radiotherapy for high grade glioma [J]. Ann Palliat Med, 2021, 10(1): 846-862.
[4] Majchrzak K, Kaspera W, Bobek-Billewicz B, et al. The assessment of prognostic factors in surgical treatment of low-grade gliomas: a prospective study [J]. Clin Neurol Neurosurg, 2012, 114(8): 1135-1144.
[5] Jiang T, Mao Y, Ma W, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas [J]. Cancer Lett, 2016, 375(2): 263-273.
[6] Liang J, Zhang X, Xie S, et al. Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics[J]. Med Oncol, 2014, 31(4): 899.
[7] Yamaguchi S, Kobayashi H, Terasaka S, et al. The impact of extent of resection and histological subtype on the outcome of adult patients with high-grade gliomas [J]. Jpn J Clin Oncol, 2012, 42(4): 270-277.
[8] Turkoglu E, Gurer B, Sanli AM, et al. Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute [J]. Clin Neurol Neurosurg, 2013, 115(12): 2508-2513.
[9] Sun Y, Xiong ZY, Yan PF, et al. Characteristics and prognostic factors of age-stratified high-grade intracranial glioma patients: a population-based analysis [J]. Bosn J Basic Med Sci, 2019, 19(4): 375-383.
[10] Niu X, Wang T, Li J, et al. An integrative survival analysis with identification of prognostic factors in the patients with coexisting glioma and intracranial aneurysm[J]. World Neurosurg, 2018, 111: e592-e600. doi: 10.1016/j.wneu.2017.12.126
[11] Li J, Niu X, Gan Y, et al. Clinical and pathologic features and prognostic factors for recurrent gliomas [J]. World Neurosurg, 2019, 128: e21-e30. doi: 10.1016/j.wneu.2019.02.210.
[12] Choi J, Kim SH, Ahn SS, et al. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma [J]. Sci Rep, 2020, 10(1): 2086.
[13] Eckert M, Klumpp L, Huber SM. Cellular effects of the antiepileptic drug valproic acid in glioblastoma [J]. Cell Physiol Biochem, 2017, 44(4): 1591-1605.
[14] Hoja S, Schulze M, Rehli M, et al. Molecular dissection of the valproic acid effects on glioma cells [J]. Oncotarget, 2016, 7(39): 62989-63002.
[15] Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme [J]. J Neurosurg, 2013, 118(4): 859-865.
[16] Luo Y, Wang H, Zhao X, et al. Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway [J]. Toxicol Res(Camb), 2016, 5(3): 859-870.
[17] Romain B, Benbrika-Nehmar R, Marisa L, et al. Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer: impact on tumor growth and cell migration [J]. Oncotarget, 2017, 8(24): 38351-38366.
[18] Liu G, Wang H, Zhang F, et al. The effect of VPA on increasing radiosensitivity in osteosarcoma cells and primary-culture cells from chemical carcinogen-induced breast cancer in rats [J]. Int J Mol Sci, 2017, 18(5):1027. doi: 10.3390/ijms18051027.
[19] Shoji M, Ninomiya I, Makino I, et al. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma [J]. Int J Oncol, 2012, 40(6): 2140-2146.
[20] Sun L, He Q, Tsai C, et al. HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via upregulating somatostatin receptor II [J]. Am J Transl Res, 2018, 10(2): 545-553.
[21] Sanaei M, Kavoosi F, Roustazadeh A, et al. In vitro effect of the histone deacetylase inhibitor valproic acid on viability and apoptosis of the PLC/PRF5 human hepatocellular carcinoma cell line [J].Asian Pac J Cancer Prev, 2018, 19(9): 2507-2510.
[22] Riva G, Cilibrasi C, Bazzoni R, et al. Valproic acid inhibits proliferation and reduces invasiveness in glioma stem cells through wnt/β catenin signalling activation [J]. Genes(Basel), 2018, 9(11): 522. doi: 10.3390/genes9110522.
[23] Liu G, Lim D, Cai Z, et al. The valproate mediates radio-bidirectional regulation through RFWD3-dependent ubiquitination on rad51 [J]. Front Oncol, 2021, 11: 646256. doi: 10.3389/fonc.2021.646256.
[24] Cai Z, Lim D, Liu G, et al. Valproic acid-like compounds enhance and prolong the radiotherapy effect on breast cancer by activating and maintaining anti-tumor immune function [J]. Front Immunol, 2021, 12: 646384. doi: 10.3389/fimmu.2021.646384.
[25] Terranova-Barberio M, Roca MS, Zotti AI, et al. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression [J]. Oncotarget, 2016, 7(7): 7715-7731.
[26] Ryu CH, Yoon WS, Park KY, et al. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells [J]. J Biomed Biotechnol, 2012, 2012: 987495. doi: 10.1155/2012/987495.
[27] Plazibat M, Katuši c Bojanac A, Himerleich Peri c M, et al. Embryo-derived teratoma in vitro biological system reveals antitumor and embryotoxic activity of valproate [J]. FEBS J, 2020, 287(21): 4783-4800.
[28] Abaza MS, Bahman AM, Al-Attiyah RJ. Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms [J]. Int J Mol Med, 2014, 34(2): 513-532.
[29] Peng J, Cai Z, Zhao R, et al. The intervention of valproic acid on the tumorigenesis induced by an environmental carcinogen of PAHs [J]. Toxicol Res(Camb), 2020, 9(5): 609-621.
[30] Luo Z, Wang Z, He X, et al. Effects of histone deacetylase inhibitors on regenerative cell responses in human dental pulp cells[J]. Int Endod J, 2018,51(7):767-778.
[31] Tian Y, Liu G, Wang H, et al. Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway[J]. DNA Repair(Amst), 2017, 58: 1-12. doi: 10.1016/j.dnarep.2017.08.002.
[32] Redjal N, Reinshagen C, Le A, et al. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade Ⅱ/Ⅲ gliomas treated with temozolomide[J]. J Neuro-Oncol, 2016, 127(3): 505-514.
[1] 聂思月,王震,孙靖宇,刘杰,李娟,魏小娟,路春晓,吕兴龑,王淑云,孙玉萍. ANGPTL5在人胃癌组织中的表达及临床意义[J]. 山东大学学报(医学版), 2017, 55(8): 61-65.
[2] 王雯,刘尧,龙飞,马卫霞,苏莉莉. 外周血淋巴细胞/单核细胞比值与恶性胸膜间皮瘤患者预后的关系[J]. 山东大学学报(医学版), 2016, 54(8): 72-77.
[3] 张伟, 周勇, 牛俊婕, 徐英, 侯华英, 姜玉华. 抗癫痫药丙戊酸钠对大鼠正常脑组织的放射保护作用[J]. 山东大学学报(医学版), 2015, 53(10): 11-15.
[4] 郑懿,蒋伟,金讯波,王慕文,张沂南,夏庆华. 丙戊酸诱导前列腺癌自噬并促进SPARCL1蛋白的表达[J]. 山东大学学报(医学版), 2013, 51(7): 32-35.
[5] 牛俊婕1,王晗1,2,徐英1,周勇1,姜玉华1. 丙戊酸钠增强大鼠胶质瘤C6细胞放射敏感性的体外实验[J]. 山东大学学报(医学版), 2013, 51(06): 15-19.
[6] 郑鲲鹏1,宋辉2,樊明德1,张源3,李科1,王成伟1. h17细胞相关因子在人脑胶质瘤中的测定[J]. 山东大学学报(医学版), 2012, 50(6): 87-91.
[7] 张晶晶,马道新,孔海丽,王慧君,孙元欣,刘传方. 靶向AML1/ETO的siRNA增强Kasumi-1细胞对组蛋白去乙酰化酶抑制剂的敏感性[J]. 山东大学学报(医学版), 2011, 49(7): 68-73.
[8] 黄忠献,金讯波,王慕文,张沂南,郑懿,夏庆华. 丙戊酸对前列腺癌PC3细胞自噬的影响[J]. 山东大学学报(医学版), 2011, 49(7): 44-47.
[9] 王汉斌1,2,庞琦2,富壮1,赵光宇2,丁锋2,栾立明2,郭华2,许家军2,许尚臣2 . 雄黄体外诱导C6胶质瘤细胞凋亡的特点及分析[J]. 山东大学学报(医学版), 2010, 48(1): 21-.
[10] 高德轩 夏庆华 吕家驹 张辉. 丙戊酸长期给药对抑制PC3细胞系裸鼠移植瘤生长的影响[J]. 山东大学学报(医学版), 2008, 46(12): 1158-1161.
[11] 杨高原,荣风年,周婷. 丙戊酸对卵巢癌裸鼠移植瘤血管形成的影响[J]. 山东大学学报(医学版), 2008, 46(11): 1034-1036.
[12] 赵珊,荣风年,周婷 . 丙戊酸对人卵巢癌裸鼠移植瘤的抑制作用[J]. 山东大学学报(医学版), 2007, 45(3): 306-309.
[13] 耿洁,时昌文,荣风年 . 丙戊酸对体外培养的卵巢癌细胞上皮性钙粘附素表达的影响[J]. 山东大学学报(医学版), 2006, 44(7): 739-742.
[14] 庞琦,王汉斌,葛明旭,司志超,朱玉方,张康,魏广福,张志明. 雄黄治疗胶质瘤的初步试验研究[J]. 山东大学学报(医学版), 2006, 44(4): 376-379.
[15] 姜政,胡锦,李新钢,卢大儒,江玉泉. SYBR Green实时定量PCR检测人脑原发胶质瘤中LATS1和LATS2基因的表达[J]. 山东大学学报(医学版), 2006, 44(12): 1289-1293.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1 -6 .
[2] 张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7 -14 .
[3] 龙婷婷,谢明,周璐,朱俊德. Noggin蛋白对小鼠脑缺血再灌注损伤后学习和记忆能力与齿状回结构的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 15 -23 .
[4] 付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24 -31 .
[5] 马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32 -37 .
[6] 李宁,李娟,谢艳,李培龙,王允山,杜鲁涛,王传新. 长链非编码RNA AL109955.1在80例结直肠癌组织中的表达及对细胞增殖与迁移侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 38 -46 .
[7] 史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47 -52 .
[8] 肖娟,肖强,丛伟,李婷,丁守銮,张媛,邵纯纯,吴梅,刘佳宁,贾红英. 两种甲状腺超声数据报告系统诊断效能的比较[J]. 山东大学学报 (医学版), 2020, 1(7): 53 -59 .
[9] 丁祥云,于清梅,张文芳,庄园,郝晶. 胰岛素样生长因子II在84例多囊卵巢综合征患者颗粒细胞中的表达和促排卵结局的相关性[J]. 山东大学学报 (医学版), 2020, 1(7): 60 -66 .
[10] 徐玉香,刘煜东,张蓬,段瑞生. 101例脑小血管病患者脑微出血危险因素的回顾性分析[J]. 山东大学学报 (医学版), 2020, 1(7): 67 -71 .